The density of Tbet+ tumor-infiltrating T lymphocytes reflects an effective and druggable preexisting adaptive antitumor immune response in colorectal cancer, irrespective of the microsatellite status-Reference-Cited by-同舟云学术

The density of Tbet+ tumor-infiltrating T lymphocytes reflects an effective and druggable preexisting adaptive antitumor immune response in colorectal cancer, irrespective of the microsatellite status

Published:2019-01-19 Issue:4 Volume:8 Page:e1562834
ISSN:2162-402X
Container-title:OncoImmunology
language:en
Short-container-title:OncoImmunology

Author:

Ott Eva¹,Bilonda Linda²³,Dansette Delphine¹,Deleine Cécile²,Duchalais Emilie⁴⁵,Podevin Juliette⁴⁵,Volteau Christelle⁶,Bennouna Jaafar⁴⁷,Touchefeu Yann⁴⁸,Fourquier Pierre⁹,El Alami Thomas Wassila¹⁰,Chetritt Jérome¹⁰,Bezieau Stéphane⁷¹¹,Denis Marc⁷¹¹,Toquet Claire¹⁷,Mosnier Jean-François¹⁷,Jarry Anne²,Bossard Céline¹²⁷

Affiliation:

1. Service d’Anatomie et Cytologie Pathologiques, Centre Hospitalier Universitaire Hôtel Dieu, Nantes, France

2. CRCINA, INSERM, Université d’Angers, Université de Nantes, Nantes, France

3. Institut Roche, Boulogne-Billancourt, France

4. Institut des Maladies de l’Appareil Digestif, Oncologie Digestive, Centre Hospitalier Universitaire Hôtel Dieu, Nantes, France

5. Service de Chirurgie digestive et endocrinienne, Centre Hospitalier Universitaire Hôtel Dieu, Nantes, France

6. Plateforme de Biométrie, Centre Hospitalier Universitaire Hôtel Dieu, Nantes, France

7. Faculté de Médecine, Université de Nantes, Nantes, France

8. Service d’Hépato-Gastroentérologie, Centre Hospitalier Universitaire Hôtel Dieu, Nantes, France

9. Service de Chirurgie Viscérale et Digestive, Hôpital privé du Confluent, Nantes, France

10. Institut d’Histopathologie, Nantes, France

11. Plateforme de Génétique moléculaire des cancers, Centre Hospitalier Universitaire Hôtel Dieu, Nantes, France

Funder

Cancéropole Grand Ouest

Ligue contre le cancer

DHU Oncogreffe CHU Nantes

Roche and ANRT

Publisher

Informa UK Limited

Subject

Oncology,Immunology,Immunology and Allergy

Link

https://tandfonline.com/doi/pdf/10.1080/2162402X.2018.1562834

Reference64 articles.

1. Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy

2. The B7-H1 (PD-L1) T Lymphocyte-Inhibitory Molecule Is Expressed in Breast Cancer Patients with Infiltrating Ductal Carcinoma: Correlation with Important High-Risk Prognostic Factors

3. Immunohistochemical localization of programmed death-1 ligand-1 (PD-L1) in gastric carcinoma and its clinical significance

4. Programmed cell death 1 ligand 1 and tumor-infiltrating CD8+ T lymphocytes are prognostic factors of human ovarian cancer

5. Clinical Significance and Therapeutic Potential of the Programmed Death-1 Ligand/Programmed Death-1 Pathway in Human Pancreatic Cancer

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Comparative study of [18F]AlF-PAI-PDL1p and [68Ga]Ga-PAI-PDL1p as novel PD-L1 targeting PET probes for tumor imaging;Bioorganic Chemistry;2024-10

2. Colorectal medullary carcinoma: a pathological subtype with intense immune response and potential to benefit from immune checkpoint inhibitors;Expert Review of Clinical Immunology;2024-03-13

3. Use of patient-derived explants as a preclinical model for precision medicine in colorectal cancer: A scoping review;Langenbeck's Archives of Surgery;2023-10-10

4. Defining the Immune Checkpoint Landscape in Human Colorectal Cancer Highlights the Relevance of the TIGIT/CD155 Axis for Optimizing Immunotherapy;Cancers;2022-08-31

5. Reconnaissance of tumor immune microenvironment spatial heterogeneity in metastatic renal cell carcinoma and correlation with immunotherapy response;Clinical and Experimental Immunology;2021-02-09